|
1
|
Leboulleux S, Baudin E, Travagli JP and
Schlumberger M: Medullary thyroid carcinoma. Clin Endocrinol (Oxf).
61:299–310. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Santarpia L, Ye L and Gagel RF: Beyond
RET: Potential therapeutic approaches for advanced and metastatic
medullary thyroid carcinoma. J Intern Med. 266:99–113. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Wells SA Jr, Asa SL, Dralle H, Elisei R,
Evans DB, Gagel RF, Lee N, Machens A, Moley JF, Pacini F, et al;
American Thyroid Association Guidelines Task Force on Medullary
Thyroid Carcinoma, . Revised American Thyroid Association
guidelines for the management of medullary thyroid carcinoma.
Thyroid. 25:567–610. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Drosten M and Pützer BM: Mechanisms of
disease: Cancer targeting and the impact of oncogenic RET for
medullary thyroid carcinoma therapy. Nat Clin Pract Oncol.
3:564–574. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Iorio MV and Croce CM: Causes and
consequences of microRNA dysregulation. Cancer J. 18:215–222. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Santarpia L, Calin GA, Adam L, Ye L, Fusco
A, Giunti S, Thaller C, Paladini L, Zhang X, Jimenez C, et al: A
miRNA signature associated with human metastatic medullary thyroid
carcinoma. Endocr Relat Cancer. 20:809–823. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Chu YH, Hardin H, Schneider DF, Chen H and
Lloyd RV: MicroRNA-21 and long non-coding RNA MALAT1 are
overexpressed markers in medullary thyroid carcinoma. Exp Mol
Pathol. 103:229–236. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Spitschak A, Meier C, Kowtharapu B,
Engelmann D and Pützer BM: MiR-182 promotes cancer invasion by
linking RET oncogene activated NF-κB to loss of the HES1/Notch1
regulatory circuit. Mol Cancer. 16:242017. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Duan L, Hao X, Liu Z, Zhang Y and Zhang G:
MiR-129-5p is down-regulated and involved in the growth, apoptosis
and migration of medullary thyroid carcinoma cells through
targeting RET. FEBS Lett. 588:1644–1651. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ke Y, Zhao W, Xiong J and Cao R: miR-149
inhibits non-small-cell lung cancer cells EMT by targeting FOXM1.
Biochem Res Int. 2013:5067312013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Yang D, Du G, Xu A, Xi X and Li D:
Expression of miR-149-3p inhibits proliferation, migration, and
invasion of bladder cancer by targeting S100A4. Am J Cancer Res.
7:2209–2219. 2017.PubMed/NCBI
|
|
12
|
Wang Y, Zheng X, Zhang Z, Zhou J, Zhao G,
Yang J, Xia L, Wang R, Cai X, Hu H, et al: MicroRNA-149 inhibits
proliferation and cell cycle progression through the targeting of
ZBTB2 in human gastric cancer. PLoS One. 7:e416932012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Tian P and Yan L: Inhibition of
MicroRNA-149-5p induces apoptosis of acute myeloid leukemia cell
line THP-1 by targeting fas ligand (FASLG). Med Sci Monit.
22:5116–5123. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Shen X, Li J, Liao W, Wang J, Chen H, Yao
Y, Liu H and Ding K: microRNA-149 targets caspase-2 in glioma
progression. Oncotarget. 7:26388–26399. 2016.PubMed/NCBI
|
|
15
|
Manabe R, Kovalenko M, Webb DJ and Horwitz
AR: GIT1 functions in a motile, multi-molecular signaling complex
that regulates protrusive activity and cell migration. J Cell Sci.
115:1497–1510. 2002.PubMed/NCBI
|
|
16
|
Tao WY, Wang CY, Sun YH, Su YH, Pang D and
Zhang GQ: MicroRNA-34c suppresses breast cancer migration and
invasion by targeting GIT1. J Cancer. 7:1653–1662. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Li J, Wang Q, Wen R, Liang J, Zhong X,
Yang W, Su D and Tang J: MiR-138 inhibits cell proliferation and
reverses epithelial-mesenchymal transition in non-small cell lung
cancer cells by targeting GIT1 and SEMA4C. J Cell Mol Med.
19:2793–2805. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Tu XM, Gu YL and Ren GQ: miR-125a-3p
targetedly regulates GIT1 expression to inhibit osteoblastic
proliferation and differentiation. Exp Ther Med. 12:4099–4106.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Chan SH, Huang WC, Chang JW, Chang KJ, Kuo
WH, Wang MY, Lin KY, Uen YH, Hou MF, Lin CM, et al: MicroRNA-149
targets GIT1 to suppress integrin signaling and breast cancer
metastasis. Oncogene. 33:4496–4507. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Volinia S, Visone R, Galasso M, Rossi E
and Croce CM: Identification of microRNA activity by Targets'
Reverse EXpression. Bioinformatics. 26:91–97. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Lu J, Getz G, Miska EA, Alvarez-Saavedra
E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA,
et al: MicroRNA expression profiles classify human cancers. Nature.
435:834–838. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Bartel DP: MicroRNAs: Target recognition
and regulatory functions. Cell. 136:215–233. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Luo Z, Zhang L, Li Z, Li X, Li G, Yu H,
Jiang C, Dai Y, Guo X, Xiang J, et al: An in silico analysis of
dynamic changes in microRNA expression profiles in stepwise
development of nasopharyngeal carcinoma. BMC Med Genomics. 5:32012.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Jin L, Hu WL, Jiang CC, Wang JX, Han CC,
Chu P, Zhang LJ, Thorne RF, Wilmott J, Scolyer RA, et al:
MicroRNA-149*, a p53-responsive microRNA, functions as an oncogenic
regulator in human melanoma. Proc Natl Acad Sci USA.
108:15840–15845. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Xu K, Liu X, Mao X, Xue L, Wang R, Chen L
and Chu X: MicroRNA-149 suppresses colorectal cancer cell migration
and invasion by directly targeting forkhead box transcription
factor FOXM1. Cell Physiol Biochem. 35:499–515. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Luo G, Chao YL, Tang B, Li BS, Xiao YF,
Xie R, Wang SM, Wu YY, Dong H, Liu XD, et al: miR-149 represses
metastasis of hepatocellular carcinoma by targeting
actin-regulatory proteins PPM1F. Oncotarget. 6:37808–37823. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Gu YL, Rong XX, Wen LT, Zhu GX and Qian
MQ: miR-195 inhibits the proliferation and migration of
chondrocytes by targeting GIT1. Mol Med Rep. 15:194–200. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Yang X, Ye J, Yan H, Tang Z, Shen J, Zhang
J and Yang L: MiR-491 attenuates cancer stem cell-like properties
of hepatocellular carcinoma by inhibition of GIT-1/NF-κB-mediated
EMT. Tumour Biol. 37:201–209. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Huang WC, Chan SH, Jang TH, Chang JW, Ko
YC, Yen TC, Chiang SL, Chiang WF, Shieh TY, Liao CT, et al:
miRNA-491-5p and GIT1 serve as modulators and biomarkers for oral
squamous cell carcinoma invasion and metastasis. Cancer Res.
74:751–764. 2014. View Article : Google Scholar : PubMed/NCBI
|
